Quantitative imaging for better outcomes
Welcome to the website of the Vogel-Claussen Heart and Lung Imaging Lab in the Institute for Diagnostic and Interventional Radiology at Hannover Medical School.
The team develops innovative, quantitative imaging markers for improved patient care. We focus on pioneering and maturing innovative techniques and imaging biomarkers for the assessment of lung and cardiovascular function and microstructure to establish novel endpoints in clinical trials. We create fully automated pipelines for the extraction of high-yield imaging biomarkers for large scale trials and clinical translation.
Our vision is to gain new insights into cardiovascular and pulmonary diseases to improve patient outcome.
Prof. Dr. med. Jens Vogel-Claussen
At the annual meeting 2019, the ISMRM has awarded Dr. Andreas Voskrebenzev, physicist of Vogel-Claussen Imaging Lab, the Summa Cum Laude Merit Award for his research on quantification of regional lung ventilation using proton MRI.
Abstract title "FEV1/FVC Mapping with Dynamic MRI - A New Regional Lung Function Test"
Coauthors: Agilo Kern, Lea Behrendt, Filip Klimeš, Marcel Gutberlet, Gesa Pöhler, Frank Wacker, Jens Vogel-Claussen
We are part of a collaboration which could show the effect of Indacaterol/Glycopyrronium on pulmonary perfusion and ventilation in COPD patients. This in turn can be expected to also lead to an improvement of cardiac function.
We thank our collaborators at Hannover Medical School (Dept. of Respiratory Medicine, Dept. of Cardiology, Dept. of Cardiac, Thoracic, Transplantation, and Vascular Surgery, Department of Pediatric Pneumology, Allergology and Neonatology, Department of Nuclear Medicine, Department of Pathology), in Hannover (Fraunhofer ITEM, CHERH) in Germany (Gießen University, Heidelberg University, LMU Munich, Mainz University, Regensburg University), Europe (Sheffield University, Erasmus University Rotterdam, AKH Vienna, Amsterdam UMC, University Hospital Zurich) and overseas (Columbia University, Johns Hopkins Medical School, University of Toronto) as well as our funding sources (DZL, BMBF, NIH, IFB-Tx, DFG, REBIRTH, foundations and industry) for successful translational research and continued support.